Why NeurAxis, Inc.’s (NRXS) Stock Is Down 5.12%
As of Monday, October 19, NeurAxis, Inc.’s NRXS share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Commentary & Analysis
Why NeurAxis, Inc.’s (NRXS) Stock Is Up 12.48%
As of Thursday, October 15, NeurAxis, Inc.’s NRXS share price has surged by 12.48%, which has investors questioning if this is right time to sell.Michael Rose
Why NeurAxis, Inc.’s (NRXS) Stock Is Up 11.79%
As of Thursday, October 15, NeurAxis, Inc.’s NRXS share price has surged by 11.79%, which has investors questioning if this is right time to sell.Jenna Brashear
Why NeurAxis, Inc.’s (NRXS) Stock Is Up 7.30%
As of Tuesday, September 29, NeurAxis, Inc.’s NRXS share price has surged by 7.30%, which has investors questioning if this is right time to sell.Jenna Brashear
Why NeurAxis, Inc.’s (NRXS) Stock Is Up 10.23%
As of Thursday, September 17, NeurAxis, Inc.’s NRXS share price has surged by 10.23%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | NRXS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $89.5 | $383.9 | 21% |
|
| Shares Out (Mil) | 12.1 | 40.6 | 23% |
|
| Institutional Ownership | 43.1% | 83.3% | 18% |
|
| Float (Mil) | 8.3 | 35.1 | 17% |
|
| Beta | 1.47 | 0.90 | 81% |
|
| Avg Daily Volume (000s) | 92 | 323 | 36% |
|
| Price Change (52-week) |
136.1% | 62.8% | 97% |
|
| Growth | NRXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 13.6% | 11.8% | 70% |
|
| Net Income (5yr) | (16.1%) | (5.6%) | 24% |
|
| EPS (5yr) | 12.9% | 10.6% | 52 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (32.0%) | (15.6%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.210) | ($0.760) | ($0.270) | |
| Month Ago EPS | ($0.210) | ($0.760) | ($0.270) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.115) | ($0.680) | ($0.060) | |
| Year/Year Chg | 11.7% | (19.8%) | (132.7%) | |
| Financials | NRXS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $141 | 6% |
|
| Net Income (TTM) (Mil) | ($8) | ($10) | 31% |
|
| EPS (TTM) | ($0.776) | ($0.400) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($2) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $25 | 12% |
|
| Enterprise Value (Q1) (Mil) | $72 | $381 | 19% |
|
| Valuation | NRXS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.20 | 2.46 | 93% |
|
| P/E | na | 28.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | NRXS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 85.6% | 59.3% | 91% |
|
| Net Margin | (144.4%) | (6.9%) | 6% |
|
| ROA | (89.9%) | (12.1%) | 6% |
|
| ROE | (139.9%) | (10.3%) | 6% |
|
| Liabilities to Assets | 32.6% | 47.2% | 24% |
|
| F-Score | 4 | 4 | 34% |
|
NeurAxis, Inc. did not pass any screens on 10/30/2026.
